FIELD: medicine.
SUBSTANCE: invention refers to medicine, more specifically to therapy of diseases and conditions accompanied by oxidative stress. Disclosed is use of a pharmaceutical composition containing 18 ml of molecular hydrogen, 0.05-2.0 ml of nitrogen oxide and 1-20 ml of platymix per 1 l of 0.9% sterile sodium chloride solution, by introducing it into a human body for treating diseases and conditions accompanied by oxidative stress.
EFFECT: more effective effect of the composition on reducing oxidative stress processes.
4 cl, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF LACTOBACILLUS FERMENTUM U-21 STRAIN CELLS FOR PREVENTION OF PATHOLOGIC TISSUE CHANGE CAUSED BY OXIDATIVE STRESS | 2019 |
|
RU2757118C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING REPRODUCTIVE AND ERECTILE DYSFUNCTIONS IN MEN AND USE THEREOF | 2023 |
|
RU2825382C1 |
| ANTIOXIDANT, STRESS- AND NEUROPROTECTIVE PHARMACOLOGICAL AGENT POTASSIUM COMENATE | 2012 |
|
RU2514632C1 |
| METHOD FOR PREPARING LITHIUM SALT OF COMENIC ACID AND USING IT AS ANTIOXIDANT, STRESS- AND NEUROPROTECTIVE AGENT | 2011 |
|
RU2477722C1 |
| AGENT, USE THEREOF AND A METHOD OF INCREASING RESISTANCE OF A MAMMALIAN ORGANISM TO ISCHEMIC-REPERFUSION INVOLVEMENT OF THE SMALL INTESTINE | 2018 |
|
RU2729788C2 |
| METHOD FOR REDUCING THE RISK OF DEVELOPMENT OF POSTOPERATIVE RELAPSE OF LOWER LIMB VARICOSE VEINS IN C4-C6 CLINICAL CLASSES | 2022 |
|
RU2793061C1 |
| LACTOBACILLUS FERMENTUM U-21 STRAIN, WHICH PRODUCES COMPLEX OF BIOLOGICALLY ACTIVE SUBSTANCES WHICH NEUTRALIZE SUPEROXIDE ANION INDUCED BY CHEMICAL AGENTS | 2018 |
|
RU2705250C2 |
| ANTIOXIDANT, STRESS AND NEUROPROTECTIVE PHARMACOLOGICAL AGENT SODIUM COMENATE | 2012 |
|
RU2506078C1 |
| METHOD OF QUANTITATIVE ASSESSMENT OF BALANCE OF PRO- AND ANTIOXIDANTS IN BRAIN DIVISIONS OF ANIMAL | 2013 |
|
RU2523403C1 |
| ANTIOXIDANTS COMPOSITION SUITABLE FOR ORAL ADMINISTRATION IN THERAPY OF INFLAMMATORY PROCESS IN LUNGS | 2018 |
|
RU2684783C1 |
